PEGylated Paclitaxel Nanomedicine Meets 3D Confinement: Cytotoxicity and Cell Behaviors
Source abstract
Abstract
Investigating the effect of nanomedicines on cancer cell behavior in three-dimensional (3D) platforms is beneficial for evaluating and developing novel antitumor nanomedicines in vitro. While the cytotoxicity of nanomedicines on cancer cells has been widely studied on two-dimensional flat surfaces, there is little work using 3D confinement to assess their effects. This study aims to address this gap by applying PEGylated paclitaxel nanoparticles (PEG-PTX NPs) for the first time to treat nasopharyngeal carcinoma (NPC43) cells in 3D confinement consisting of microwells with different sizes and a glass cover. The cytotoxicity of the small molecule drug paclitaxel (PTX) and PEG-PTX NPs was studied in microwells with sizes of 50 × 50, 100 × 100, and 150 × 150 μm2 both with and without a concealed top cover. The impact of microwell confinement with varying sizes and concealment on the cytotoxicity of PTX and PEG-PTX NPs was analyzed by assessing NPC43 cell viability, migration speed, and cell morphology following treatment. Overall, microwell isolation was found to suppress drug cytotoxicity, and differences were observed in the time-dependent effects of PTX and PEG-PTX NPs on NPC43 cells in isolated and concealed microenvironments. These results not only demonstrate the effect of 3D confinement on nanomedicine cytotoxicity and cell behaviors but also provide a novel method to screen anticancer drugs and evaluate cell behaviors in vitro.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · 3D Printing in Biomedical Research · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Electrical Engineering, City University of Hong Kong, Hong Kong, China
Centre for Biosystems, Neuroscience, and Nanotechnology, City University of Hong Kong, Hong Kong, China
Funding
Center for Biosystems, Neuroscience, and Nanotechnology (CBNN) of City University of Hong Kong · The University Grants Council of Hong Kong
References (49)
Show source-provided references
1. Kargozar, S., Mollazadeh, S., Kermani, F., Webster, T.J., Nazarnezhad, S., Hamzehlou, S., and Baino, F. (2022). Hydroxyapatite nanoparticles for improved cancer theranostics. J. Funct. Biomater., 13.10.3390/jfb13030100 ↗
2. Heterogeneous trimetallic nanoparticles as catalysts10.1021/acs.chemrev.1c00493 ↗
3. Tailoring nanoparticles based on boron dipyrromethene for cancer imaging and therapy10.1002/wnan.1627 ↗
4. Engineering a Nano/Biointerface for Cell and Organ-Selective Drug Delivery10.1021/acs.langmuir.2c01609 ↗
5. Calzoni, E., Cesaretti, A., Polchi, A., Di Michele, A., Tancini, B., and Emiliani, C. (2019). Biocompatible polymer nanoparticles for drug delivery applications in cancer and neurodegenerative disorder therapies. J. Funct. Biomater., 10.10.3390/jfb10010004 ↗
6. Obstacles and opportunities in a forward vision for cancer nanomedicine10.1038/s41563-021-01047-7 ↗
7. Multifunctional biomolecule nanostructures for cancer therapy10.1038/s41578-021-00315-x ↗
8. Recent advances in polymeric nanomedicines for cancer immunotherapy10.1002/adhm.201801320 ↗
9. Supramolecular Combination Chemotherapy: Cucurbit[8]uril Complex Enhanced Platinum Drug Infiltration and Modified Nanomechanical Property of Colorectal Cancer Cells10.1021/acs.langmuir.2c02388 ↗
10. Clinical translation of nanomedicine10.1021/acs.chemrev.5b00116 ↗
11. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel
12. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel10.1158/1078-0432.CCR-05-1634 ↗
13. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies10.1158/1078-0432.CCR-03-0655 ↗
14. In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy10.1016/S0168-3659(01)00275-9 ↗
15. Single cell arrays of hematological cancer cells for assessment of lymphocyte cytotoxicity dynamics, serial killing, and extracellular molecules10.1039/C9LC00133F ↗
16. Acoustic Droplet-Assisted Superhydrophilic–Superhydrophobic Microarray Platform for High-Throughput Screening of Patient-Derived Tumor Spheroids10.1021/acsami.1c06655 ↗
17. Tailoring materials with specific wettability in biomedical engineering10.1002/advs.202100126 ↗
18. Application and development of shape memory micro/nano patterns10.1002/smll.202105958 ↗
19. Trends in droplet microfluidics: From droplet generation to biomedical applications10.1021/acs.langmuir.2c00491 ↗
20. Rapid prototyping of concave microwells for the formation of 3D multicellular cancer aggregates for drug screening10.1002/adhm.201300151 ↗
21. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week10.1038/s41467-021-22676-1 ↗
22. Vertically Coated Graphene Oxide Micro-Well Arrays for Highly Efficient Cancer Spheroid Formation and Drug Screening10.1002/adhm.201901751 ↗
23. A dynamic 3D tumor spheroid chip enables more accurate nanomedicine uptake evaluation10.1002/advs.201901462 ↗
24. Concave microwell array-mediated three-dimensional tumor model for screening anticancer drug-loaded nanoparticles10.1016/j.nano.2015.02.009 ↗
25. Dynamics of natural killer cells cytotoxicity in microwell arrays with connecting channels10.3389/fimmu.2017.00998 ↗
26. Single-cell analysis of the dynamics and functional outcomes of interactions between human natural killer cells and target cells10.1039/c2ib20167d ↗
27. Optimization, characterization and in vivo evaluation of paclitaxel-loaded folate-conjugated superparamagnetic iron oxide nanoparticles10.2147/IJN.S287434 ↗
28. Timosaponin AIII Suppresses RAP1 Signaling Pathway to Enhance the Inhibitory Effect of Paclitaxel on Nasopharyngeal Carcinoma
29. SPLUNC1 and MLL3 regulate cancer stem cells in nasopharyngeal carcinoma
30. Epstein-Barr virus (EBV)-encoded small RNAs (EBERs) associated with poor prognosis of head and neck carcinomas10.18632/oncotarget.16033 ↗
31. Natural killer cell migration control in microchannels by perturbations and topography10.1039/C9LC00356H ↗
32. A dual-responsive nanocapsule via disulfide-induced self-assembly for therapeutic agent delivery10.1039/C5SC03707G ↗
33. PEGylated BODIPY assembling fluorescent nanoparticles for photodynamic therapy10.1016/j.cclet.2017.06.017 ↗
34. Engineering pH-responsive BODIPY nanoparticles for tumor selective multimodal imaging and phototherapy10.1021/acsami.9b16403 ↗
35. The effect of molecular structure on cytotoxicity and antitumor activity of PEGylated nanomedicines10.1021/acs.biomac.8b00083 ↗
36. Reduction-sensitive amphiphilic copolymers made via multi-component Passerini reaction for drug delivery10.1016/j.colsurfb.2014.12.030 ↗
37. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: Preparation and comparison with other paclitaxel systems in vitro and in vivo10.1016/j.ijpharm.2014.05.032 ↗
38. Simultaneous quantitative analysis of polyethylene glycol (PEG), PEGylated paclitaxel and paclitaxel in rats by MS/MSALL technique with hybrid quadrupole time-of-flight mass spectrometry10.1016/j.jpba.2017.06.053 ↗
39. Effects of PEGylated paclitaxel nanocrystals on breast cancer and its lung metastasis10.1039/C4NR07450E ↗
40. Probing the relevance of 3D cancer models in nanomedicine research10.1016/j.addr.2014.06.007 ↗
41. The past, present, and future of breast cancer models for nanomedicine development10.1016/j.addr.2021.03.018 ↗
42. Inhibition of metastasis and growth of breast cancer by pH-sensitive poly (β-amino ester) nanoparticles co-delivering two siRNA and paclitaxel10.1016/j.biomaterials.2015.01.049 ↗
43. CircEXOC6B suppresses the proliferation and motility and sensitizes ovarian cancer cells to paclitaxel through miR-376c-3p/FOXO3 axis
44. Enhanced motility and interaction of nasopharyngeal carcinoma with epithelial cells in confined microwells10.1039/D2LC00616B ↗
45. Biomaterials offer cancer research the third dimension10.1038/nmat2619 ↗
46. Engineered silk fibroin protein 3D matrices for in vitro tumor model10.1016/j.biomaterials.2010.11.052 ↗
47. Comparison of 2D-and 3D-culture models as drug-testing platforms in breast cancer10.3892/or.2015.3767 ↗
48. In vitro toxicity testing of nanoparticles in 3D cell culture10.1002/smll.200801788 ↗
49. Evaluation of photodynamic therapy efficiency using an in vitro three-dimensional microfluidic breast cancer tissue model10.1039/C4LC01065E ↗